9F1 Stock Overview
Operates as a biotechnology company in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Diagonal Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0025 |
| 52 Week High | SEK 0.047 |
| 52 Week Low | SEK 0.0006 |
| Beta | -2.1 |
| 11 Month Change | -16.67% |
| 3 Month Change | 25.00% |
| 1 Year Change | -89.75% |
| 33 Year Change | -99.62% |
| 5 Year Change | n/a |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9F1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.8% | 0.8% | -1.3% |
| 1Y | -89.8% | -17.5% | 7.4% |
Return vs Industry: 9F1 underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 9F1 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 9F1 volatility | |
|---|---|
| 9F1 Average Weekly Movement | 45.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9F1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9F1's weekly volatility has increased from 32% to 46% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4 | Karin Wehlin | diagonalbio.com |
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports.
Diagonal Bio AB (publ) Fundamentals Summary
| 9F1 fundamental statistics | |
|---|---|
| Market cap | €1.13m |
| Earnings (TTM) | -€879.75k |
| Revenue (TTM) | €104.36k |
10.9x
P/S Ratio-1.3x
P/E RatioIs 9F1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9F1 income statement (TTM) | |
|---|---|
| Revenue | SEK 1.21m |
| Cost of Revenue | -SEK 58.00k |
| Gross Profit | SEK 1.27m |
| Other Expenses | SEK 11.47m |
| Earnings | -SEK 10.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 104.79% |
| Net Profit Margin | -842.98% |
| Debt/Equity Ratio | 0% |
How did 9F1 perform over the long term?
See historical performance and comparison